Effect of Losartan on Progression of Emphysema
氯沙坦对肺气肿进展的影响
基本信息
- 批准号:10004773
- 负责人:
- 金额:$ 36.45万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-08-01 至 2021-08-31
- 项目状态:已结题
- 来源:
- 关键词:AlveolarAngiotensin ReceptorAngiotensinsAnti-Inflammatory AgentsAntihypertensive AgentsApoptosisBiologicalBronchial SpasmBronchodilator AgentsCause of DeathChronic BronchitisChronic Obstructive Airway DiseaseClinicalClinical ResearchClinical TrialsCommunitiesConsentControlled Clinical TrialsData CollectionData QualityDatabasesDevelopmentDiagnostic radiologic examinationDiseaseDisease ProgressionEpithelialExhibitsGoalsHeterogeneityHigh Resolution Computed TomographyHospitalizationIndividualInstitutional Review BoardsLeadershipLosartanLungManualsMeasuresMediatingMediator of activation proteinMonitorMorbidity - disease rateMulti-Institutional Clinical TrialMusNeptunePatientsPeripheralPharmaceutical PreparationsPharmacologyPhenotypePilot ProjectsPlacebosPreventionProceduresProtocols documentationPulmonary EmphysemaPulmonary Function Test/Forced Expiratory Volume 1RandomizedReceptor ActivationReportingResearchRespiratory MusclesRespiratory physiologySafetyScanningSignal TransductionSkeletal MuscleSpirometryStandardizationStructureStructure of parenchyma of lungSubgroupSuggestionSystemTestingTrainingTransforming Growth Factor betaUnited StatesUnited States National Institutes of HealthX-Ray Computed Tomographyairway inflammationcardiovascular risk factorcigarette smokedesigndisabilitydistributed dataexposure to cigarette smokefibrillininterestirbesartanlung volumemortalitymuscle strengthpatient subsetspragmatic trialpreclinical studypreventpublic health relevancereceptorreduce symptomssecondary analysissmoking cessationsymptom treatmenttreatment effectweb site
项目摘要
DESCRIPTION (provided by applicant): Chronic Obstructive Pulmonary Disease (COPD) is a major cause of death and disability in the United States. Current treatments target bronchospasm and inflammation of airways with the goal to reduce symptoms and prevent exacerbations. However, other than smoking cessation, no treatment has been found that modifies the progression of this disease. Moreover, COPD is a heterogeneous disease involving remodeling of both lung parenchyma (emphysema) and airways (chronic bronchitis). Research in mice exposed to cigarette smoke implicates TGF-beta signaling as a mediator of apoptosis that leads to emphysema. The development of emphysema can be prevented by blockade of the angiotensin-1 (AT1) receptor with drugs such as losartan. A pilot study of losartan in patients with COPD showed no overall improvement, but patients who had the emphysema phenotype demonstrated no progression of emphysema at 1 year compared to placebo treated patients who increased the percent of lung occupied by emphysema. These results did not reach statistical significance (p = 0.06) but were strongly suggestive of a benefit in COPD patients with emphysema. The aim of this proposal is to conduct a definitive randomized, placebo-controlled, clinical trial to test whether administration of 100mg/day of losartan to patients with radiographic evidence of emphysema will slow progression of their disease compared to comparable individuals given placebo. Emphysema progression will be measured by high-resolution computed tomography using standardized procedures. The trial is designed to be a highly-focused pragmatic trial with sparse data collection that can be accomplished in community as well as academic settings.
项目成果
期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Losartan Effects on Emphysema Progression Randomized Clinical Trial: Rationale, Design, Recruitment, and Retention.
- DOI:10.15326/jcopdf.2021.0210
- 发表时间:2021-08
- 期刊:
- 影响因子:0
- 作者:R. Wise;J. Holbrook;Robert H. Brown;G. Criner;M. Dransfield;M. Han;J. Krishnan;E. Looney;E. Neptune;Vicky Palombizio;Alexis L Rea
- 通讯作者:R. Wise;J. Holbrook;Robert H. Brown;G. Criner;M. Dransfield;M. Han;J. Krishnan;E. Looney;E. Neptune;Vicky Palombizio;Alexis L Rea
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Janet T. Holbrook其他文献
Macular Edema Ranibizumab versus Intravitreal Anti-inflammatory Therapy Trial: 24-Week Outcomes of Uveitic Macular Edema Re-treatment
雷珠单抗与玻璃体内抗炎治疗对比试验:葡萄膜炎性黄斑水肿再次治疗的24周结果
- DOI:
10.1016/j.ophtha.2024.11.021 - 发表时间:
2025-05-01 - 期刊:
- 影响因子:9.500
- 作者:
The Multicenter Uveitis Steroid Treatment Trial (MUST) Research Group;John Gonzales;Nisha R. Acharya;Elizabeth A. Sugar;Alyce E. Burke;Albert T. Vitale;Vishali Gupta;James P. Dunn;Susan L. Lightman;Jennifer E. Thorne;Rosa Y. Kim;Steven Yeh;Michael M. Altaweel;John H. Kempen;Janet T. Holbrook;Douglas A. Jabs - 通讯作者:
Douglas A. Jabs
Intravitreal Therapy for Uveitic Macular Edema—Ranibizumab versus Methotrexate versus the Dexamethasone Implant: The MERIT Trial Results
葡萄膜炎性黄斑水肿的玻璃体内治疗——雷珠单抗与甲氨蝶呤与地塞米松植入物:MERIT 试验结果
- DOI:
10.1016/j.ophtha.2023.04.011 - 发表时间:
2023-09-01 - 期刊:
- 影响因子:9.500
- 作者:
The Multicenter Uveitis Steroid Treatment Trial (MUST) Research Group, Writing Committee:;Nisha R. Acharya;Albert T. Vitale;Elizabeth A. Sugar;Janet T. Holbrook;Alyce E. Burke;Jennifer E. Thorne;Michael M. Altaweel;John H. Kempen;Douglas A. Jabs - 通讯作者:
Douglas A. Jabs
THE RELATIONSHIP BETWEEN ASTHMA AND RHINITIS/RHINOSINUSITIS
- DOI:
10.1378/chest.128.4_meetingabstracts.147s-a - 发表时间:
2005-10-01 - 期刊:
- 影响因子:
- 作者:
Anne E. Dixon;David A. Kaminsky;Janet T. Holbrook;Robert A. Wise;David M. Shade;Charles G. Irvin - 通讯作者:
Charles G. Irvin
Correction to: electronic cigarette use behaviors and motivations among smokers and non-smokers
- DOI:
10.1186/s12889-018-5048-y - 发表时间:
2018-01-24 - 期刊:
- 影响因子:3.600
- 作者:
Thomas E. Sussan;Fatima G. Shahzad;Eefa Tabassum;Joanna E. Cohen;Robert A. Wise;Michael J. Blaha;Janet T. Holbrook;Shyam Biswal - 通讯作者:
Shyam Biswal
Janet T. Holbrook的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Janet T. Holbrook', 18)}}的其他基金
ADalimumab Vs. conventional ImmunoSupprEssion for uveitis(ADVISE) Trial
阿达木单抗对比。
- 批准号:
10480091 - 财政年份:2018
- 资助金额:
$ 36.45万 - 项目类别:
ADalimumab Vs. conventional ImmunoSupprEssion for uveitis(ADVISE) Trial
阿达木单抗对比。
- 批准号:
10002234 - 财政年份:2018
- 资助金额:
$ 36.45万 - 项目类别:
Macular Edema Treatment Trials Associated with MUST (META-MUST)
与 MUST 相关的黄斑水肿治疗试验 (META-MUST)
- 批准号:
8996746 - 财政年份:2014
- 资助金额:
$ 36.45万 - 项目类别:
Macular Edema Treatment Trials Associated with MUST (META-MUST)
与 MUST 相关的黄斑水肿治疗试验 (META-MUST)
- 批准号:
9211348 - 财政年份:2014
- 资助金额:
$ 36.45万 - 项目类别:
Macular Edema Treatment Trials Associated with MUST (META-MUST)
与 MUST 相关的黄斑水肿治疗试验 (META-MUST)
- 批准号:
8986226 - 财政年份:2014
- 资助金额:
$ 36.45万 - 项目类别:
Study of Acid Reflux Therapy for Children with Asthma
儿童哮喘胃酸反流治疗研究
- 批准号:
6904865 - 财政年份:2006
- 资助金额:
$ 36.45万 - 项目类别:
Study of Acid Reflux Therapy for Children with Asthma
儿童哮喘胃酸反流治疗研究
- 批准号:
7878064 - 财政年份:2006
- 资助金额:
$ 36.45万 - 项目类别:
Study of Acid Reflux Therapy for Children with Asthma
儿童哮喘胃酸反流治疗研究
- 批准号:
7637446 - 财政年份:2006
- 资助金额:
$ 36.45万 - 项目类别:
Study of Acid Reflux Therapy for Children with Asthma
儿童哮喘胃酸反流治疗研究
- 批准号:
7288749 - 财政年份:2006
- 资助金额:
$ 36.45万 - 项目类别:
相似海外基金
Exploratory Efficacy-Evaluation Study of Angiotensin Receptor-Neprilysin Inhibitor in patients with dialysis
血管紧张素受体脑啡肽酶抑制剂在透析患者中的探索性疗效评价研究
- 批准号:
21K16191 - 财政年份:2021
- 资助金额:
$ 36.45万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Personalizing Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Therapy in Chronic Kidney Disease
慢性肾脏病的个体化血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂治疗
- 批准号:
10313873 - 财政年份:2021
- 资助金额:
$ 36.45万 - 项目类别:
Strategies for Angiotensin Receptor Blocker Mediated Tissue Repair
血管紧张素受体阻滞剂介导的组织修复策略
- 批准号:
10469311 - 财政年份:2020
- 资助金额:
$ 36.45万 - 项目类别:
Impact of an Angiotensin Receptor Blocker in Aortic Stenosis - a Randomized Controlled Trial
血管紧张素受体阻滞剂对主动脉瓣狭窄的影响 - 一项随机对照试验
- 批准号:
433568 - 财政年份:2020
- 资助金额:
$ 36.45万 - 项目类别:
Operating Grants
Strategies for Angiotensin Receptor Blocker Mediated Tissue Repair
血管紧张素受体阻滞剂介导的组织修复策略
- 批准号:
10649490 - 财政年份:2020
- 资助金额:
$ 36.45万 - 项目类别:
Strategies for Angiotensin Receptor Blocker Mediated Tissue Repair
血管紧张素受体阻滞剂介导的组织修复策略
- 批准号:
10210299 - 财政年份:2020
- 资助金额:
$ 36.45万 - 项目类别:
Strategies for Angiotensin Receptor Blocker Mediated Tissue Repair
血管紧张素受体阻滞剂介导的组织修复策略
- 批准号:
10065083 - 财政年份:2020
- 资助金额:
$ 36.45万 - 项目类别:
Mechanism of suppressive effects for atherosclerosis by Angiotensin Receptor-Neprilysin Inhibitor
血管紧张素受体脑啡肽酶抑制剂抑制动脉粥样硬化的机制
- 批准号:
19K17618 - 财政年份:2019
- 资助金额:
$ 36.45万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Pathophysiological significance of angiotensin receptor-binding protein in leucocytes and immune cells
白细胞和免疫细胞中血管紧张素受体结合蛋白的病理生理意义
- 批准号:
19K17575 - 财政年份:2019
- 资助金额:
$ 36.45万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Angiotensin receptor G protein signal switching in AgRP neurons in cardiometabolic control
AgRP 神经元中血管紧张素受体 G 蛋白信号转换在心脏代谢控制中的作用
- 批准号:
10658260 - 财政年份:2017
- 资助金额:
$ 36.45万 - 项目类别: